RIGEL PHARMACEUTICALS INC — Director's Dealing 2023

Jan 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2023-01-26

Reporting Person: Schorno Dean L (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-26	Common Stock	A	63000	—	Acquired	201908	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-26	Employee Stock Option (right to buy)	$2.42	A	50000	Acquired	2032-01-24	Common Stock (50000)	Direct
2023-01-26	Employee Stock Option (right to buy)	$1.87	A	125000	Acquired	2033-01-26	Common Stock (125000)	Direct

Footnotes

F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024.

F2: Includes 10,000 shares acquired under the issuer's stock purchase plan.

F3: The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met.

F4: The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met.

F5: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period.